EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Early growth response 1 (EGR1) has dual roles as a tumor suppressor or oncogene.
• Its function in rhabdomyosarcoma (RMS), a pediatric muscle cancer, is not fully understood.
• EGR1 expression differs between RMS subtypes: downregulated in alveolar RMS (ARMS) and comparable to normal muscle in embryonal RMS (ERMS).

Purpose of the Study:

• To investigate the role of EGR1 in rhabdomyosarcoma (RMS) subtypes.
• To elucidate the mechanisms by which EGR1 influences RMS cell behavior.
• To assess the therapeutic potential of EGR1 modulation in RMS.

Main Methods:

• Gene expression analysis in RMS subtypes.
• Overexpression of EGR1 in ARMS cell lines.
• Analysis of cell proliferation, migration, and anchorage-independent growth.
• Co-immunoprecipitation to study protein interactions.
• Apoptosis assays and Western blotting to examine apoptosis pathways.
• Assessment of sensitivity to chemotherapeutic agents.

Main Results:

• EGR1 is downregulated in ARMS compared to ERMS and normal muscle.
• EGR1 overexpression in ARMS reduced proliferation, migration, and anchorage-independent growth, and promoted differentiation.
• EGR1 interacts with the oncogene TBX2, inhibiting EGR1-dependent gene expression, including cell cycle regulators (p21, PTEN) and growth drivers (NDRG1, CST6).
• EGR1 induced apoptosis via the intrinsic pathway by activating BAX and dephosphorylated BAD.
• EGR1 sensitized RMS cells to chemotherapy.

Conclusions:

• EGR1 functions as a tumor suppressor in ARMS.
• EGR1's tumor-suppressive activity is partly mediated by inhibiting TBX2 and promoting apoptosis.
• EGR1 modulation, particularly its activation, holds therapeutic potential for RMS, potentially sensitizing cells to chemotherapy.